ABATTIS BIOCEUTICALS CORP

ABATTIS BIOCEUTICALS CORP

OOTC:ATTBF
0.00
USD
0.00
(0.00%)
0.00EPS
8.65MMarket Cap

Total Valuation

USD

As of September 30, 2019, ABATTIS BIOCEUTICALS CORP carries a market capitalization of 8.65M, placing it among publicly traded companies globally. Its enterprise value stands at 7.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.65M
Enterprise Value7.71M

Share Statistics

As of September 30, 2019, ABATTIS BIOCEUTICALS CORP has 477.80M shares outstanding.

Shares Outstanding477.80M

Valuation Ratios

These figures are as of September 30, 2019. The price-to-sales ratio is 31.59, and the price-to-book ratio stands at 1.03.

PS Ratio31.59
PB Ratio1.03
P/TBV Ratio-3.03
P/FCF Ratio2.59
P/OCF Ratio1.20

Enterprise Valuation

These figures are as of September 30, 2019. The EV/Sales ratio of 28.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.71M versus a market cap of 8.65M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales28.60

Financial Position

As of September 30, 2019, ABATTIS BIOCEUTICALS CORP maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.71, indicating elevated leverage, while an interest coverage ratio of -74.10 demonstrates limited ability to service its debt obligations.

Current Ratio0.73
Quick Ratio0.52
Debt / Equity14.71
Debt / EBITDA-0.44
Interest Coverage-74.10

Financial Efficiency

USD

Over the twelve months ended September 30, 2019, ABATTIS BIOCEUTICALS CORP posted a negative return on equity (ROE) of -26.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.84, reflecting losses generated across the asset base. The company generates approximately 269,588.60 in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-26.96
Return on Assets (ROA)-19.84
Revenue Per Employee269,588.60
Employee Count1.00

Taxes

USD

Over the twelve months ended September 30, 2019, ABATTIS BIOCEUTICALS CORP recorded 3,873.00 in income tax expense. The company reported a pretax loss of -2.31M and -2.30M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax3,873.00

Stock Price Statistics

USD

As of the close on November 16, 2026, ABATTIS BIOCEUTICALS CORP's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at -NaN, while the 200-day moving average is 0.00.

50-Day Moving Average-NaN

Income Statement

USD

Over the twelve months ended September 30, 2019, ABATTIS BIOCEUTICALS CORP generated 269,588.60 in revenue and converted that into -2.30M in net income, yielding earnings per share of 0.00. EBITDA reached -2.71M, while operating income came in at -3.03M.

Revenue269,588.60
Operating Income-3.03M
Pretax Income-2.31M
Net Income-2.30M
EBITDA-2.71M
EBIT-2.79M

Balance Sheet

USD

As of September 30, 2019, ABATTIS BIOCEUTICALS CORP holds 1.81M in cash and equivalents against 1.19M in total debt, resulting in a net debt position of -453,774.80. Total book value stands at 8.37M, with working capital of -989,864.63 providing operational flexibility.

Cash & Cash Equivalents1.81M
Total Debt1.19M
Net Debt-453,774.80
Equity (Book Value)8.37M
Book Value Per Share0.02
Working Capital-989,864.63

Cash Flow

USD

ABATTIS BIOCEUTICALS CORP produced 7.11M in operating cash flow over the twelve months ended September 30, 2019. After subtracting -3.82M in capital expenditures, free cash flow totaled 3.29M - equivalent to 0.01 per share.

Operating Cash Flow7.11M
Capital Expenditures-3.82M
Free Cash Flow3.29M
FCF Per Share0.01

Margins

These figures cover the twelve months ended September 30, 2019. The operating margin of -1,125.03 and net profit margin of -852.40 provide insight into operational efficiency.

Operating Margin-1,125.03
Pretax Margin-857.72
Profit Margin-852.40
EBITDA Margin-1,005.27

Dividends & Yields

These figures cover the twelve months ended September 30, 2019. Free cash flow yield stands at 38.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.52, meaning ABATTIS BIOCEUTICALS CORP raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.52
FCF Yield38.59

Stock Splits

ABATTIS BIOCEUTICALS CORP's most recent stock split took place on September 11, 2012 with a 5:1 split ratio.

Last Split Date9/11/2012
Split Ratio5:1

Scores

As of September 30, 2019, ABATTIS BIOCEUTICALS CORP has an Altman Z-Score of -34.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-34.77